...
首页> 外文期刊>International journal of psychiatry in clinical practice >Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder
【24h】

Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder

机译:哌醋甲酯治疗对注意力缺陷多动障碍儿童和青少年食欲和瘦素,生长素释放肽,脂联素和脑源性神经营养因子的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives. We aimed to explore whether the use of methylphenidate relates leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor (BDNF). In addition, the relationship between methylphenidate-related weight loss in attention deficit hyperactivity disorder (ADHD) patients and these biomolecules were evaluated. Methods. Thirty ADHD patients receiving methylphenidate and 20 healthy controls were included. Leptin, ghrelin, adiponectin, and BDNF levels were measured at baseline and aft er two-month treatment in both groups. Results. At baseline, leptin, ghrelin, adiponectin, and BDNF levels were similar in the ADHD and control groups. The most common adverse events occurring in the ADHD group aft er a 2-month treatment period included loss of appetite (70%) and weight loss (66.7%). A significant difference was found in body weight, BMI, and CGI scores of the ADHD patients aft er the treatment. While post-treatment ghrelin and adiponectin levels were significantly higher in the ADHD group, BDNF level was significantly lower. Post-treatment decrease in leptin levels was not significant. Conclusions. Leptin and BDNF were not associated with poor appetite and/or weight loss due to methylphenidate treatment. However, ghrelin and adiponectin might be biomolecules that play a role in underlying neurobiological mechanisms of methylphenidate-related appetite or weight loss.
机译:目标。我们旨在探讨哌醋甲酯的使用是否与瘦素,生长素释放肽,脂联素和脑源性神经营养因子(BDNF)相关。此外,评估了注意力缺陷多动障碍(ADHD)患者的哌醋甲酯相关体重减轻与这些生物分子之间的关系。方法。包括30名接受哌醋甲酯的ADHD患者和20名健康对照。两组均在基线和治疗后两个月测量瘦素,生长素释放肽,脂联素和BDNF水平。结果。在基线时,ADHD组和对照组的瘦素,生长素释放肽,脂联素和BDNF水平相似。在治疗2个月后的ADHD组中,最常见的不良事件包括食欲不振(70%)和体重减轻(66.7%)。在治疗后,ADHD患者的体重,BMI和CGI得分存在显着差异。尽管ADHD组的治疗后生长素释放肽和脂联素水平显着较高,而BDNF水平显着较低。治疗后瘦素水平下降不明显。结论瘦素和BDNF与哌醋甲酯治疗引起的食欲不振和/或体重减轻无关。然而,生长素释放肽和脂联素可能是在与哌醋甲酯相关的食欲或体重减轻的潜在神经生物学机制中起作用的生物分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号